- Home
- Companies
- usa hawaii
- t cell subtypes from naive t cells
Show results for
Refine by
T Cell Subtypes From Naive T Cells Suppliers Serving Usa Hawaii
63 companies found
based inSeoul, SOUTH KOREA
Eutilex is Developing anti-tumor T cell therapy and antibody therapeutics based on its own proprietary immunotherapy technology We set a goal to be a leading company in anti-tumor immunotherapy markets through the technical innovation & early ...
4th generation GPC3 CAR-T shows better efficacy compared to 2nd generation GPC3 CAR-T; Shows better efficacy for tumor clearance than 2nd generation GPC3 CAR-T in vivo; Clear anti-cancer efficacy in an orthotopic model; Smaller number of 4th ...
based inPalo Alto, CALIFORNIA (USA)
Immune-Onc is a clinical-stage company developing a novel class of myeloid checkpoint inhibitors. We believe myeloid checkpoints are the next frontier of immunotherapy for cancer. In collaboration with scientists, our research team is among the ...
Immune-Onc is evaluating IO-108, an antagonist antibody targeting the myeloid checkpoint, LILRB2 (also known as ILT4). The U.S. FDA has cleared the IND application for IO-108 as a potential therapy for solid tumors. The company expects to begin ...
based inBerkeley, CALIFORNIA (USA)
Indee Labs is developing a non-viral, intracellular delivery system based on microfluidic vortex shedding (µVS) to rapidly deliver nucleic acids, proteins and gene editing complexes with minimal perturbation. The technology is used by global ...
Hydropore™ is a simple, scalable and efficient way to accelerate the discovery, development and manufacturing of gene-modified cell therapies (GMCTs) such as T cell immunotherapies. This novel, non-viral technology utilizes the ...
based inCambridge, MASSACHUSETTS (USA)
Editas Medicine is a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of medicines for people living with serious diseases around ...
based inMont-Saint-Guibert, BELGIUM
Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. We are developing a diversified pipeline of allogeneic and autologous CAR T cell ...
CYAD-203 is a preclinical, non-gene edited allogeneic CAR T candidate and our first armored CAR T candidate engineered to co-express the cytokine interleukin-18 (IL-18) with the NKG2D CAR receptor. IL-18 is a proinflammatory cytokine that directly ...
based inSeattle, WASHINGTON (USA)
AVM Biotechnology is developing and advancing AVM0703, a proprietary formulation of concentrated dexamethasone. This formulation permits the very high dosing necessary to activate the release and trigger the production of the body’s supercharged ...
based inMenlo Park, CALIFORNIA (USA)
Adicet is a biotechnology company engaged in the development of first-in-class off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet has developed a proprietary cell platform process to activate, engineer and ...
based inOlathe, KANSAS (USA)
TVAX Biomedical is a clinical stage development company advancing its novel targeted cell-based immunotherapy for the treatment of cancer. TVAX Biomedical is developing a paradigm-shifting cancer treatment that offers the promise of improved ...
based inUtrecht, NETHERLANDS
At LAVA, we are focused on applying our expertise in gamma-delta T cell engagers. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor ...
Our lead program, LAVA-051, is a unique, humanized gamma-delta bsTCE targeting CD1d-expressing tumors, including multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML). We have achieved preclinical proof-of-concept ...
based inPhiladelphia, PENNSYLVANIA (USA)
A clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases Cabaletta Bio seeks to employ its specifically targeted CAAR (Chimeric AutoAntibody Receptor) T ...
based inSan Carlos, CALIFORNIA (USA)
CellFE is a venture-backed company with a mission to make advanced therapies accessible to all by transforming the way gene therapies are manufactured. The company uses a microfluidics-based cell engineering platform that can be adapted universally ...
based inBeachwood, OHIO (USA)
We develop cell therapies - at a dramatically increased speed, at lower cost, and with less R&D risk. Trailhead Biosystems merges developmental biology and cell therapeutics with cutting-edge hardware and computerized experimental design and ...
We are developing cell culture media for T-cell subtype control to improve clinical potency in the individual patient and reduction of variability in outcomes between patients. CAR T-cell therapy involves the treatment of cancer by modifying a ...
based inGaithersburg, MARYLAND (USA)
NexImmune is a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIMâ„¢) technology. AIM nanoparticles act as synthetic dendritic cells to deliver ...
The injectable modality (AIM INJ) is an injectable pharmaceutical product of AIM nanoparticles decorated with antigen-specific peptides and co-stimulatory molecules appropriate for the disease being targeted. Based on specific size and ...
based inWoburn, MASSACHUSETTS (USA)
ImmunoDX, LLC (IDX) - formerly known as ImmunoDiagnostics - develops, manufactures and markets a wide range of specialty biologicals for Human T-cell Research/ Diagnostics, AIDS, HCV, HBV, TB, Cancer and Arthritis diagnostics and therapeutics ...
based inSeattle, WASHINGTON (USA)
We believe we are entering a new era of medicine. The ability to modify genes and use cells as medicines provides new tools to meaningfully change the outcome of many human diseases. Early pioneers have made good progress, but most of what we can ...
Oncology: Non-Hodgkin lymphoma (NHL), Acute lymphoblastic leukemia (ALL), Chronic lymphocytic leukemia ...
based inSan Francisco, CALIFORNIA (USA)
We were founded with the mission of creating a world without infectious disease. We are a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. ...
We are exploiting the unique immunology of human cytomegalovirus, or HCMV, a commonly occurring virus in humans, as a delivery vehicle – or vector – for vaccines to potentially treat and prevent infection by pathogens that are refractory ...
based inTuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
Patients eligible for clinical trials with ACTengine® product candidates have a portion of their white blood cells collected using a well-established process called leukapheresis, a procedure in which a fraction of the white blood cells of a ...
based inParis, FRANCE
Enterome is pioneering the discovery and development of novel pharmaceuticals based on its unrivalled understanding of the interaction between the gut microbiome and the immune system – the Microbiome-Immunoinflammation Axis. Enterome is using this ...
OncoMimicsTM vaccines are a specific combination of bacterial peptides, derived from bacteria present in the gut microbiome, that closely mimic either overexpressed tumor-associated antigens (TAAs) or lineage-specific markers in solid and liquid ...
based inNew York, NEW YORK (USA)
IN8bio was founded in 2016 with the mission of developing novel therapies to address cancer. The company is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T-cell product ...
INB-100, our DeltEx Allo, is an allogeneic product candidate, initially developed for the treatment of patients with acute leukemia undergoing hematopoietic stem cell transplantation (HSCT). This is the first clinical trial of an expanded and ...
based inPlanegg, GERMANY
TQ Therapeutics GmbH is pioneering a novel approach to cell and gene therapy with its TQx platform, which transforms the production of cellular therapies into a rapid, automated process that occurs at the patient's side. This method leverages ...